What is the recommended stimulant treatment algorithm for an adult with attention‑deficit/hyperactivity disorder?

Stimulant Treatment Algorithm for Adult ADHD

Start with methylphenidate (MPH) 5 mg or amphetamine/dextroamphetamine (AMP/DEX) 2.5 mg twice daily (after breakfast and lunch), then titrate upward weekly by 5-10 mg increments until symptoms resolve or side effects emerge, with maximum daily doses typically reaching 60 mg for MPH or 40 mg for AMP/DEX. 1

Initial Assessment Requirements

Before initiating stimulants, document:

• Core ADHD symptoms present since childhood (before age 7 per DSM criteria)
• Moderate to severe functional impairment in at least two settings (work, home, social)
• Detailed substance use history with consideration of urine drug screen
• Collateral information from spouse, significant other, or family member (adults with ADHD often underestimate symptom severity)
• Baseline blood pressure, pulse, height, and weight 1

Critical caveat: Adults with ADHD have notoriously poor insight into their symptoms—always obtain third-party information 1.

Absolute Contraindications

Do not prescribe stimulants if:

• Previous hypersensitivity to stimulants
• Glaucoma
• Symptomatic cardiovascular disease
• Hyperthyroidism or uncontrolled hypertension
• Current MAO inhibitor use
• Active psychotic disorder
• History of illicit stimulant abuse (unless in controlled/supervised setting) 1

Phase I: Medication Selection and Initiation

First-Line Choice

Either methylphenidate or amphetamine/dextroamphetamine may be selected based on clinician and patient preference. However, amphetamines typically cause greater appetite suppression and sleep disruption due to longer half-lives 1.

Starting Doses for Adults

• Methylphenidate: 5 mg twice daily (morning and noon)
• Amphetamine/Dextroamphetamine: 2.5 mg once daily in early morning, adding noon dose if needed 1

Phase II: Systematic Titration

Weekly Titration Schedule

Week 1: Start at initial dose
Week 2: Increase to 10 mg MPH or 5 mg AMP/DEX
Week 3: Increase to 15 mg MPH or 7.5 mg AMP/DEX
Week 4: Increase to 20 mg MPH or 10 mg AMP/DEX
Week 5+: Continue titration in 5-10 mg increments until optimal response 1

Monitoring at Each Visit

• ADHD symptom ratings from patient and significant other
• Side effect assessment
• Blood pressure and pulse (quarterly minimum)
• Contact can be via phone between visits 1

Maximum Doses

Adults typically require similar total daily doses to children, with some patients requiring:

• MPH: Up to 60-65 mg/day or 1.0 mg/kg
• AMP/DEX: Up to 40 mg/day or 0.9 mg/kg

Adults may need higher total daily doses than children because they require coverage over a longer working day 1.

Alternative Titration Strategy: Forced Titration

Give patient all four dose levels (MPH: 5,10,15,20 mg OR AMP/DEX: 2.5,7.5,10 mg), each for 1 week. At follow-up, review all rating scales and select the dose producing maximum benefit with minimal side effects 1.

Phase III: Optimization

Dosing Schedule Adjustments

• Add third afternoon dose (around 4 PM) for homework/evening activities coverage
• Adjust timing to minimize appetite suppression at dinner and sleep onset delay
• Consider long-acting formulations for maintenance to improve adherence and reduce abuse potential 1

When to Stop Upward Titration

Stop increasing dose when:

1. Symptoms resolve and functional impairment diminishes
2. Troublesome side effects emerge
3. Maximum recommended dose reached without benefit 1

Phase IV: If Inadequate Response

Before Switching Medications

Ensure adequate trial:

• Sufficient dose reached
• Adequate duration (at least 1 week per dose level)
• Good medication adherence
• No confounding comorbid conditions (bipolar disorder, depression, personality disorders, substance abuse) 1

Switching Stimulants

If MPH fails, trial AMP/DEX (or vice versa) using same titration algorithm. The two stimulant classes have different mechanisms and individual response varies 1.

Second-Line: Nonstimulants

If both stimulant classes fail or are contraindicated, consider atomoxetine 2.

Critical Monitoring During Maintenance

Quarterly

• Blood pressure and pulse by treating or primary care physician 1

Annually

• Height and weight
• Comprehensive physical examination 1

Ongoing

• Substance abuse screening in high-risk patients
• Medication diversion risk assessment (especially if household members have substance use history) 1

Common Pitfalls to Avoid

1. Undertitration: Many clinicians stop at subtherapeutic doses—continue titrating until symptoms resolve or side effects emerge
2. Inadequate trial duration: Each dose level requires at least one week for assessment
3. Ignoring collateral information: Adults minimize their symptoms—always get third-party input
4. Missing comorbid substance abuse: Screen thoroughly before prescribing; consider supervised administration if abuse history present 1
5. Premature switching: Optimize current stimulant fully before declaring treatment failure

Special Populations

ADHD with Comorbid Anxiety

Stimulants remain appropriate for ADHD with generalized anxiety disorder or social phobia 1.

History of Substance Abuse

Stimulants are contraindicated unless patient is in controlled setting with close supervision. Long-acting formulations reduce abuse potential compared to immediate-release 1.